Duchenne Muscular Dystrophy What can we do for our sick children and what should we not do ?
نویسنده
چکیده
Professor Rudolf Korinthenberg is medical director of the Department for Child Neurology and chief of the muscle clinic at the Center for Pediatrics and Youth Medicine at the University of Freiburg in Germany. On 15 February 2006, Dr. Guenter Scheuerbrandt spoke to Professor Korinthenberg about the possibilities which are now available to the parents and the doctors for treating and managing a Duchenne boy as long as there is still no effective cure for the disease. The following text is a shortened version of the recorded interview which has been approved by Professor Korinthenberg for the information of the Duchenne families and their care givers. The questions of Dr. Scheuerbrandt are printed in italics.
منابع مشابه
مدیر موفق کیست؟
Who is a really successful manager? A manager who spends less money, or the one who earns more? A manager who can survive for a longer period of time, or an administrator who expands his organization, and opens up new branches? Which one is the most successful? The article tries to answer these questions and provides, some simple guidlines for the managers in every domain of management who wan...
متن کاملDiagnostic and therapeutic challenges for dermatologists: What shall we do when we don’t know what to do?
What shall we do when we have done everything we could for the diagnosis and treatment of a patient, but were not successful? What shall we do when there is no definite treatment for a patient? What shall we do when we have no diagnosis or treatment for a patient? Some useful suggestions are presented here to get rid of these situations.
متن کاملRepression-free utrophin-A 5’UTR variants
Mutation in the dystrophin gene results Duchenne Muscular Dystrophy (DMD), an X-linked fatal neuromuscular disorder. Dystrophin deficiency can be compensated by upregulation of utrophin, an autosomal homologue of dystrophin. But the expression of utrophin in adults is restricted to myotendinous and neuromuscular junctions. Therefore utrophin upregulation throughout the muscle fiber can only be ...
متن کاملIt Ain’t What You Do (But the Way That You Do It): Will Safety II Transform the Way We Do Patient Safety; Comment on “False Dawns and New Horizons in Patient Safety Research and Practice”
Mannion and Braithwaite outline a new paradigm for studying and improving patient safety – Safety II. In this response, I argue that Safety I should not be dismissed simply because the safety management strategies that are developed and enacted in the name of Safety I are not always true to the original philosophy of ‘systems thinking.’
متن کاملP164: Adeno-Associated Viral Vectors in Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (BMD) is an inherited X-link disease. The incidence of this muscle-wasting disease is 1:5000 male live births. Mutation in the gene coding for dystrophin is the main cause of BMD. Most cases of this disease succumb to respiratory and cardiac failure in 3rd to 4th decades. The slow progression of BMD and recent achievement of gene therapies make it as an appropriate c...
متن کامل